New drug could tame severe asthma and fungal allergy

NCT ID NCT07530770

Recruiting now Disease control Sponsor: Qianfoshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called benralizumab (Fasenra) in 20 adults with severe asthma and a fungal allergy called ABPA. The goal is to see if it can reduce asthma flare-ups that need steroids and improve quality of life. Participants receive the drug as a shot under the skin, and researchers track their progress over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Benralizumab (Fasenra), a drug given as a shot under the skin
What this could lead to: If it works, this could offer a new treatment option for people with severe asthma and ABPA, potentially reducing the need for steroids.
What could go wrong: This is a small, early-stage study with only 20 participants, so results may not apply to everyone. The drug may not work as hoped or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABPA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic bronchopulmonary aspergillosis asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABPA ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS SEVERE ASTHMA

Contacts and locations

Locations

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, 250014, China
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
RECRUITING

Jinan, Shandong, 250014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.